156 related articles for article (PubMed ID: 38203360)
1. Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma.
Zupanc C; Franko A; Štrbac D; Kovač V; Dolžan V; Goričar K
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203360
[TBL] [Abstract][Full Text] [Related]
2. The association of genetic factors with serum calretinin levels in asbestos-related diseases.
Zupanc C; Franko A; Strbac D; Kovac V; Dolzan V; Goricar K
Radiol Oncol; 2023 Dec; 57(4):473-486. PubMed ID: 38038422
[TBL] [Abstract][Full Text] [Related]
3. Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.
Kresoja-Rakic J; Kapaklikaya E; Ziltener G; Dalcher D; Santoro R; Christensen BC; Johnson KC; Schwaller B; Weder W; Stahel RA; Felley-Bosco E
Oncotarget; 2016 Apr; 7(16):21272-86. PubMed ID: 26848772
[TBL] [Abstract][Full Text] [Related]
4. Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter.
Blum W; Pecze L; Rodriguez JW; Steinauer M; Schwaller B
BMC Cancer; 2018 Apr; 18(1):475. PubMed ID: 29699512
[TBL] [Abstract][Full Text] [Related]
5. Determinants of plasma calretinin in patients with malignant pleural mesothelioma.
Lehnert M; Weber DG; Taeger D; Raiko I; Kollmeier J; Stephan-Falkenau S; Brüning T; Johnen G;
BMC Res Notes; 2020 Jul; 13(1):359. PubMed ID: 32727552
[TBL] [Abstract][Full Text] [Related]
6. Calretinin as a blood-based biomarker for mesothelioma.
Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Calretinin Expression in Human Mesothelioma Cells Reveals the Implication of the FAK and Wnt Signaling Pathways in Conferring Chemoresistance towards Cisplatin.
Wörthmüller J; Salicio V; Oberson A; Blum W; Schwaller B
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671889
[TBL] [Abstract][Full Text] [Related]
8. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.
Casjens S; Weber DG; Johnen G; Raiko I; Taeger D; Meinig C; Moebus S; Jöckel KH; Brüning T; Pesch B
BMJ Open; 2017 Oct; 7(10):e017104. PubMed ID: 29025836
[TBL] [Abstract][Full Text] [Related]
9. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
[TBL] [Abstract][Full Text] [Related]
10. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients.
Raiko I; Sander I; Weber DG; Raulf-Heimsoth M; Gillissen A; Kollmeier J; Scherpereel A; Brüning T; Johnen G
BMC Cancer; 2010 May; 10():242. PubMed ID: 20509881
[TBL] [Abstract][Full Text] [Related]
11. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
13. Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
Jiménez-Ramírez C; Gilbert Weber D; Aguilar-Madrid G; Brik A; Juárez-Pérez CA; Casjens S; Raiko I; Brüning T; Johnen G; Cabello-López A
PLoS One; 2022; 17(10):e0275936. PubMed ID: 36240245
[TBL] [Abstract][Full Text] [Related]
14. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.
Kao SC; Klebe S; Henderson DW; Reid G; Chatfield M; Armstrong NJ; Yan TD; Vardy J; Clarke S; van Zandwijk N; McCaughan B
J Thorac Oncol; 2011 Nov; 6(11):1923-9. PubMed ID: 22011651
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
[TBL] [Abstract][Full Text] [Related]
16. Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.
Cedrés S; Montero MA; Zamora E; Martínez A; Martínez P; Fariñas L; Navarro A; Torrejon D; Gabaldon A; Ramon Y Cajal S; Felip E
Clin Transl Oncol; 2014 Sep; 16(9):776-82. PubMed ID: 24323466
[TBL] [Abstract][Full Text] [Related]
17. Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
Link T; Passek S; Wimberger P; Frank K; Vassileva YD; Kramer M; Kuhlmann JD
Int J Cancer; 2020 May; 146(9):2608-2618. PubMed ID: 31509615
[TBL] [Abstract][Full Text] [Related]
18. Serum Calretinin as a Biomarker in Malignant Mesothelioma.
Zupanc C; Franko A; Štrbac D; Dodič Fikfak M; Kovač V; Dolžan V; Goričar K
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768395
[TBL] [Abstract][Full Text] [Related]
19. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
